Prelude Therapeutics PRLD
NASDAQ PRLD
$3.69 +0.16 (+4.53%)
As of: Oct 21, 2026 · 1:24 PM EDT

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026)

Updated

Prelude Therapeutics' EBITDA Margin was -264.74% in Q2 2026, up 36.26 percentage points from the prior quarter.

Analysis

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, Prelude Therapeutics' EBITDA Margin was -293.48% through Jun 30, 2026, up 1610.02 percentage points year-over-year; for FY2025, it came in at -847.24%, up 1123.36 percentage points from FY2024.

  • In earlier years, EBITDA Margin was -1970.60% in FY2024.
  • Per Business Quant data, PRLD's EBITDA Margin in the three quarters before Q2 2026 was -301.00% (Q1 2026), -300.18% (Q4 2025) and -307.58% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,134.69 Bn 1,103.27 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 616.29 Bn 534.82 Bn 17.26 Bn 35.95%
3 AbbVie 500.86 Bn 473.97 Bn 12.70 Bn 49.01%
4 Merck 366.77 Bn 321.15 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.69 Bn 261.68 Bn 11.24 Bn -
6 Astrazeneca 261.39 Bn 235.08 Bn 12.86 Bn 33.11%
7 Amgen 235.52 Bn 190.92 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.49 Bn 164.69 Bn 6.22 Bn -124.26%
9 Pfizer 169.46 Bn 116.11 Bn 10.94 Bn 39.16%
10 Prelude Therapeutics 363.05 Mn -234.25 Mn - -264.74%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -264.74%
Mar 31, 2026 -301.00%
Dec 31, 2025 -300.18%
Sep 30, 2025 -307.58%
Dec 31, 2024 -833.55%
Sep 30, 2024 -1,132.37%
API Access

Prelude Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=PRLD&period=max&api_key=YOUR_API_KEY